Trial record 2 of 8 for: "Angiomyolipoma" | "Immunosuppressive Agents"
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03525834|
Recruitment Status : Active, not recruiting
First Posted : May 16, 2018
Last Update Posted : October 15, 2019
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Active, not recruiting|
|Estimated Primary Completion Date :||October 26, 2020|
|Estimated Study Completion Date :||October 26, 2020|